Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer
Defence Therapeutics (DTCFF) has appointed Dr. Elias Theodorou as Chief Operating Officer, effective April 2025. Dr. Theodorou brings over 25 years of experience in cancer research, stem cell differentiation, and gene delivery to the biopharmaceutical company.
A Yale University Ph.D. graduate and co-founder of Protos Biologics Inc., Dr. Theodorou previously served as Director of Research at WBC Biosciences , where he co-invented methods to enhance immune cells' anticancer properties. Based in the Boston area, he will focus on advancing Defence's Accum® technology and strengthening the company's position in the US biotech market.
As part of his compensation package, Dr. Theodorou has been granted 350,000 stock options, with 100,000 vesting immediately and 250,000 vesting in one year, exercisable at $1.07 per share over ten years.
Defence Therapeutics (DTCFF) ha nominato il Dr. Elias Theodorou come Chief Operating Officer, con effetto da aprile 2025. Il Dr. Theodorou porta con sé oltre 25 anni di esperienza nella ricerca sul cancro, nella differenziazione delle cellule staminali e nella somministrazione di geni per la società biofarmaceutica.
Laureato con un dottorato all'Università di Yale e co-fondatore di Protos Biologics Inc., il Dr. Theodorou ha precedentemente ricoperto il ruolo di Direttore della Ricerca presso WBC Biosciences, dove ha co-inventato metodi per migliorare le proprietà anticancro delle cellule immunitarie. Basato nell'area di Boston, si concentrerà sull'avanzamento della tecnologia Accum® di Defence e sul rafforzamento della posizione dell'azienda nel mercato biotech statunitense.
Come parte del suo pacchetto retributivo, al Dr. Theodorou sono state concesse 350.000 opzioni azionarie, di cui 100.000 che maturano immediatamente e 250.000 che matureranno in un anno, esercitabili a $1,07 per azione nel corso di dieci anni.
Defence Therapeutics (DTCFF) ha nombrado al Dr. Elias Theodorou como Director de Operaciones, con efecto a partir de abril de 2025. El Dr. Theodorou aporta más de 25 años de experiencia en investigación del cáncer, diferenciación de células madre y entrega de genes a la empresa biofarmacéutica.
Graduado con un doctorado de la Universidad de Yale y cofundador de Protos Biologics Inc., el Dr. Theodorou se desempeñó anteriormente como Director de Investigación en WBC Biosciences, donde co-inventó métodos para mejorar las propiedades anticancerígenas de las células inmunitarias. Con sede en el área de Boston, se enfocará en avanzar la tecnología Accum® de Defence y en fortalecer la posición de la empresa en el mercado biotecnológico de EE. UU.
Como parte de su paquete de compensación, al Dr. Theodorou se le han otorgado 350,000 opciones sobre acciones, de las cuales 100,000 se consolidan de inmediato y 250,000 se consolidan en un año, ejercitables a $1.07 por acción durante diez años.
Defence Therapeutics (DTCFF)는 2025년 4월부터 Elias Theodorou 박사를 최고 운영 책임자로 임명했습니다. Theodorou 박사는 암 연구, 줄기세포 분화 및 유전자 전달 분야에서 25년 이상의 경험을 가지고 있습니다.
예일대학교에서 박사 학위를 취득하고 Protos Biologics Inc.의 공동 창립자인 Theodorou 박사는 이전에 WBC Biosciences의 연구 이사로 재직하며 면역 세포의 항암 특성을 향상시키기 위한 방법을 공동 발명했습니다. 보스턴 지역에 거주하며 Defence의 Accum® 기술을 발전시키고 미국 생명공학 시장에서 회사의 입지를 강화하는 데 집중할 것입니다.
보상 패키지의 일환으로 Theodorou 박사는 350,000주 옵션을 부여받았으며, 이 중 100,000주는 즉시 행사 가능하고 250,000주는 1년 후 행사 가능하며, 주당 $1.07에 10년 동안 행사할 수 있습니다.
Defence Therapeutics (DTCFF) a nommé le Dr Elias Theodorou au poste de directeur des opérations, à compter d'avril 2025. Le Dr Theodorou apporte plus de 25 ans d'expérience dans la recherche sur le cancer, la différenciation des cellules souches et la délivrance de gènes à l'entreprise biopharmaceutique.
Diplômé d'un doctorat de l'Université de Yale et co-fondateur de Protos Biologics Inc., le Dr Theodorou a précédemment occupé le poste de directeur de la recherche chez WBC Biosciences, où il a co-inventé des méthodes pour améliorer les propriétés anticancéreuses des cellules immunitaires. Basé dans la région de Boston, il se concentrera sur l'avancement de la technologie Accum® de Defence et sur le renforcement de la position de l'entreprise sur le marché biotechnologique américain.
Dans le cadre de son package de rémunération, le Dr Theodorou a reçu 350 000 options d'achat d'actions, dont 100 000 deviennent immédiatement acquises et 250 000 le seront dans un an, exerçables à 1,07 $ par action sur une période de dix ans.
Defence Therapeutics (DTCFF) hat Dr. Elias Theodorou zum Chief Operating Officer ernannt, mit Wirkung ab April 2025. Dr. Theodorou bringt über 25 Jahre Erfahrung in der Krebsforschung, der Differenzierung von Stammzellen und der Genübertragung in das biopharmazeutische Unternehmen ein.
Dr. Theodorou, promovierter Absolvent der Yale University und Mitbegründer von Protos Biologics Inc., war zuvor als Forschungsdirektor bei WBC Biosciences tätig, wo er Methoden zur Verbesserung der antitumoralen Eigenschaften von Immunzellen mitentwickelte. Er wird sich, ansässig im Raum Boston, auf die Weiterentwicklung der Accum®-Technologie von Defence konzentrieren und die Position des Unternehmens im US-Biotech-Markt stärken.
Als Teil seines Vergütungspakets erhielt Dr. Theodorou 350.000 Aktienoptionen, von denen 100.000 sofort und 250.000 nach einem Jahr fällig werden, ausübbar zu einem Preis von 1,07 $ pro Aktie über einen Zeitraum von zehn Jahren.
- Strategic hire of experienced COO with 25+ years expertise in relevant fields
- Expansion into US market through Boston biotech hub
- Addition of patent holder and Yale Ph.D. to executive team
- Significant stock-based compensation of 350,000 options could lead to future dilution
Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Elias Theodorou is joining the management team as the Chief Operating Officer "COO", effective in April, 2025.
Dr. Elias Theodorou, Ph.D., is a molecular biologist with over 25 years of experience in cancer research, stem cell differentiation, and gene delivery. He is the co-founder of Protos Biologics Inc., where he has been developing innovative DNA delivery systems. Previously, he served as the Director of Research at WBC Biosciences LLC, where he co-invented a method to modify innate immune cells for enhanced anticancer properties. Dr. Theodorou earned his Ph.D. from Yale University, focusing on identifying novel drivers of neural differentiation. He has authored numerous publications and holds patents related to gene therapy and protein engineering
"Dr. Theodorou's appointment as COO marks a significant milestone for Defence Therapeutics," said Sébastien Plouffe, President, CEO, and Founder of Defence Therapeutics. "His leadership, scientific acumen, and extensive experience in innovative biotech startups will be crucial in accelerating our development programs and strengthening our position in the US market. Based in the Boston area, Dr. Theodorou will spearhead our efforts to tap into the exceptional resources and expertise of the US biotech ecosystem. His ability to translate complex scientific concepts into practical applications aligns perfectly with our mission to advance the Accum® technology. We are confident that Dr. Theodorou's expertise, particularly in gene delivery and cancer research, combined with the innovative environment of the US biotech sector, will catalyze the full potential of our platform in the fields of ADCs and radioimmunoconjugates."
"I am thrilled to join Defence Therapeutics as Chief Operating Officer at this pivotal moment in the Company's growth," said Dr. Elias Theodorou. "The Accum® platform represents a groundbreaking approach in the field of drug delivery. My experience in molecular biology and innovative drug delivery systems aligns perfectly with Defence's mission. From our strategic position in the Boston biotech hub, we are poised to accelerate the development of our technology and forge crucial partnerships that will drive the next wave of cancer therapeutics. I look forward to working with the talented team at Defence to translate our scientific advancements into life-changing treatments for patients."
The Company has granted 350,000 incentive stock options to Dr. Theodorou (the "Options"), in accordance with the terms and conditions of Defence's Omnibus Incentive Plan. Of the Options, 100,000 stock option shall vest immediately, and 250,000 stock option shall vest in one year from the date of grant. The Options are exercisable at a price of
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246072
FAQ
When will Dr. Elias Theodorou start as COO of Defence Therapeutics (DTCFF)?
What are Dr. Theodorou's main responsibilities at Defence Therapeutics (DTCFF)?
What stock options were granted to Dr. Theodorou by Defence Therapeutics (DTCFF)?
What is Dr. Theodorou's background and experience before joining Defence Therapeutics (DTCFF)?
